Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.

BMC infectious diseases - 16 Oct 2024

Injinari Nastaran, Asadollahi Samira, Sefid Fateme, Arshadi Maedeh, Hosseini Saeedeh Sadat, Ghoshouni Hamed, Soltani Fatemeh, Namiranian Nasim, Sheikhha Mohammad Hasan, Aghaeimeybodi Fatemeh

Abstract excerpt

BACKGROUND: Although several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19. METHODS: In this prospective longitudinal study, 95 individuals with severe COVID-19 were selected between 2020-2022. The recovery process was measured at 24 h, 48 h, and 10 days before and after taking TCZ. All...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Longitudinal Studies

Share to Receptors, IgG

Share to Receptors, Interleukin-6

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 39415081
DOI: 10.1186/s12879-024-10073-0
PMCID: PMC11481263

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.PMID 39415081Read ↗

Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19Semantic proximity Read ↗

Genetic Biomarkers as Predictors of Response to Tocilizumab in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis.Semantic proximity Read ↗

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read ↗

The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura.Semantic proximity Read ↗

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity Read ↗

Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.Semantic proximity Read ↗

Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugsSemantic proximity Read ↗

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read ↗

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity Read ↗

Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis.Semantic proximity Read ↗

Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and ScotlandSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.